As healthcare systems across the UK and Europe continue to face mounting cost pressures and growing demands for value-based decision-making, Real-World Evidence (RWE) has emerged as a critical enabler of informed pricing, reimbursement, and market access strategies. Against this backdrop, the 2nd Annual EVIDENCE 360: RWE, Pricing and Market Access Summit, a leading Real-World Evidence conference 2026, will convene key stakeholders from across the healthcare ecosystem on 16–17 March 2026 in London.

This two-day summit is designed as a dedicated knowledge-sharing and collaboration platform for professionals navigating the evolving evidence landscape. The event brings together senior leaders from pharmaceutical and biotechnology companies, regulators, payers, health technology assessment (HTA) bodies, and digital health innovators to examine how real-world data and advanced analytics are reshaping access decisions across the UK and European markets.

Access More on 2nd Annual EVIDENCE 360: RWE, Pricing and Market Access Summit at https://realworldevidenceconference.com/upcoming-conferences/uk-edition/

Addressing the Changing Role of Real-World Evidence

With regulatory and reimbursement authorities increasingly relying on real-world insights to complement clinical trial data, the summit will focus on how RWE is being integrated into market access submissions, pricing negotiations, and post-launch evidence generation. Sessions will explore practical approaches to aligning evidence strategies with regional expectations while maintaining scientific rigor and transparency.

The agenda reflects the rapidly changing policy and regulatory environment, including the implementation of the EU HTA Regulation and Joint Clinical Assessments (JCA), as well as evolving NICE standards for RWE use in the UK. Participants will gain clarity on how these frameworks are influencing evidence requirements and decision timelines.

Why Attend

Attendees will benefit from a comprehensive program that combines strategic discussion with real-world application, including:

• In-depth case studies showcasing successful use of RWE in UK and European HTA submissions
• Strategic insights into region-specific pricing and reimbursement frameworks
• Regulatory updates on EU HTA policy developments, JCA implementation, and NICE guidance on RWE
• Exploration of emerging methodologies, including AI-driven analytics, digital endpoints, and patient-reported outcomes for evidence generation
• High-value networking opportunities with European regulators, payers, HTA experts, and market access leaders

Registration at https://realworldevidenceconference.com/upcoming-conferences/uk-edition/registration/

A Forum for Collaboration and Insight

The RWE EVIDENCE 360 Summit is positioned as more than a conference—it is a forum for dialogue, collaboration, and forward-looking strategy development. As a flagship Real-World Evidence conference 2026, it brings together diverse perspectives from across the healthcare value chain to support more robust, data-driven pricing and market access decisions. By aligning evidence strategy with regulatory and payer expectations, the RWE EVIDENCE 360 Summit aims to help organizations navigate complexity, accelerate access, and deliver sustainable value to patients and healthcare systems across the UK and Europe.